MMAE relied on the host STING pathway to enhance cGAMP antiviral immune response.

Abstract

(A-H and I-P) WT and Stinggt/gt C57BL/6 mice (n = 10) were treated with PBS, cGAMP (30 μg/mice), MMAE (0.5 mg/kg), or cGAMP along with MMAE by intraperitoneal injection (i.p.) for 2 h. Then, the mice were infected intravenously with HSV-1-GFP at 2 × 108 pfu per WT mouse or at 1 × 107 pfu per Stinggt/gt mouse. (A and I) Survival curves of virus-infected mice after treatments were analyzed using the log-rank (Mantel-Cox) test. (B, C and J, K) Body weight and body condition score of mice were observed and recorded daily. Body condition score was measured and calculated as in previous research with minor modifications [52] (normal = 0). (D-H and L-P) Six days after virus infection, three C57BL/6 mice (WT and Stinggt/gt) were randomly selected for subsequent experiments. (D and L) The viral titers in mouse brains were measured by qRT-PCR assay (n = 3 biological replicates). (E, F, M, and N) Expressions of viral genes in brains were measured by immunoblotting and qPCR analysis (n = 3). (G and O) Expressions of IFNβ and ISGs in brains were analyzed by qPCR analysis (n = 3). (H and P) IFNβ production in brains were qualified by ELISA assay.</p